e-Therapeutics (LSE:ETX) Debt-to-Revenue : 0.28 (As of Jul. 2023)

e-Therapeutics Debt-to-Revenue Chart

e-Therapeutics Annual Data
	Trend	Jan14	Jan15	Jan16	Jan17	Jan18	Jan19	Jan20	Jan21	Jan22	Jan23
Debt-to-Revenue		Get a 7-Day Free Trial					-	0.15	0.07	1.44	0.62

e-Therapeutics Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jul19	Jan20	Jul20	Jan21	Jul21	Jan22	Jul22	Jan23	Jul23
Debt-to-Revenue	Get a 7-Day Free Trial															-	N/A	0.84	0.82	0.28

Competitive Comparison of e-Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, e-Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

e-Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, e-Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where e-Therapeutics's Debt-to-Revenue falls into.

e-Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

e-Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jan. 2023 is calculated as

e-Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Jul. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jul. 2023) Revenue data.

e-Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of e-Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

e-Therapeutics (LSE:ETX) Business Description